Search

Displaying results 4751 - 4760 of 9322 in total
  1. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  2. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    efficacious than [vedolizumab] and without the CNS effects of [natalizumab]. … [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal

  3. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases. … Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist.

  4. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

  5. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell … responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498].

  6. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Results published from the CLL clinical trial failed to meet primary endpoints. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  7. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.

  8. Drug

    N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid

    go.drugbank.com/drugs/DB03458
    Experimental

    This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.

  9. Drug

    N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide

    go.drugbank.com/drugs/DB06945
    Experimental

    This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. … This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.

  10. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).